医疗器械ETF（562600）逆市上涨，持仓股迪安诊断3连板

Group 1 - The A-share market is experiencing increased divergence, with pharmaceuticals and insurance sectors leading in gains, while rare earth and photovoltaic sectors are undergoing significant adjustments. The medical device ETF (562600) has risen by 2.32%, marking its fourth consecutive day of gains, with its holding, Di'an Diagnostics, achieving three consecutive limit-up days [1] - Nvidia and Eli Lilly are set to jointly invest $1 billion over the next five years to establish an AI drug laboratory, focusing on advancing robotic technology and physical AI to accelerate medical discovery and production [1] - Huafu Securities anticipates that the start of the 14th Five-Year Plan will lead to more proactive fiscal signals, emphasizing opportunities in AI medical applications. The launch of "Ant Ai Fu" highlights the real demand for AI in healthcare, while the listing of companies like Zhizhu and miniMax indicates a new phase of capital acceleration [1] Group 2 - The medical device industry is rapidly developing, and investors can leverage the medical device ETF (562600) to capture growth opportunities. This ETF tracks the CSI All-Index Medical Device Index, with brain-computer interfaces accounting for 23.8%, the highest among listed ETFs, and the medical device sector comprising 89.2%, indicating a strong concentration that can effectively capture growth in niche markets [2] - For off-market users, options include the Huaxia CSI All-Index Medical Device ETF Initiated Link A (021250) and Huaxia CSI All-Index Medical Device ETF Initiated Link C (021251) for convenient investment [2]